Trump FDA nominee Heidi Overton struggling to win enough GOP support to be confirmed
Key Points:
- The White House has withdrawn Dr. Heidi Overton's nomination for FDA commissioner due to insufficient Senate support, particularly among Republicans in the Senate Health, Education, Labor and Pensions Committee.
- Overton faced criticism over her handling of the FDA-approved abortion drug mifepristone and her role in advancing President Trump's pro-vaping policies, leading to opposition from both anti-abortion groups and some Republican senators.
- The administration is exploring alternative candidates, including potential acting commissioners who could bypass Senate confirmation, with Sen. Roger Marshall mentioned as a possible contender.
- The FDA has been led by acting Commissioner Kyle Diamantas since the previous commissioner, Marty Makary, was ousted amid White House pressure related to flavored vape regulations.
- GOP senators remain divided on confirming a permanent FDA commissioner before losing Senate control, with concerns about the impact of short-term acting administrators on agency independence.